Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02365636 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of Topically Applied TV 45070 Ointment in Patients With Postherpetic Neuralgia (PHN)
A Phase 2 study of Postherpetic Neuralgia, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT02365636 is a Phase 2 study of Postherpetic Neuralgia that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 300 participants. The trial reports 20 study locations across 6 states.
The verdict
NCT02365636, a Phase 2 study of Postherpetic Neuralgia, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a study to evaluate the safety and efficacy of 4% and 8% w/w TV 45070 ointment compared with placebo ointment applied topically and twice daily to the area of PHN pain for 4 weeks in patients with PHN
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TV-45070
Study Locations (20)
Florida
- Teva Investigational Site 13521 - Brandon
- Teva Investigational Site 13085 - Brooksville
- Teva Investigational Site 13057 - Clearwater
- Teva Investigational Site 13084 - Fort Myers
- Teva Investigational Site 13047 - Hialeah
- Teva Investigational Site 13046 - Homestead
- Teva Investigational Site 13098 - Jacksonville
- Teva Investigational Site 13045 - Kissimmee
California
- Teva Investigational Site 13079 - Colton
- Teva Investigational Site 13331 - Pomona
- Teva Investigational Site 13341 - Sacramento
- Teva Investigational Site 13051 - Santa Monica
- Teva Investigational Site 13055 - Thousand Oaks
- Teva Investigational Site 13100 - Torrance
Alabama
- Teva Investigational Site 13052 - Birmingham
- Teva Investigational Site 13086 - Mobile
Arizona
- Teva Investigational Site 13514 - Phoenix
- Teva Investigational Site 13520 - Phoenix
Arkansas
- Teva Investigational Site 13661 - Little Rock
Connecticut
- Teva Investigational Site 13657 - Milford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2015-02-26 |
| Est. Completion | 2017-05-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02365636
The ClinicalTrials.gov registry entry for NCT02365636 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Postherpetic Neuralgia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02365636 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT02365636 about?
NCT02365636 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of Topically Applied TV 45070 Ointment in Patients With Postherpetic Neuralgia (PHN)". This is a study to evaluate the safety and efficacy of 4% and 8% w/w TV 45070 ointment compared with placebo ointment applied topically and twice daily to the area of PHN pain for 4 weeks in patients with PHN
What is the current status of trial NCT02365636?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2015-02-26. Estimated completion is 2017-05-09.
What conditions does trial NCT02365636 study?
This clinical trial studies the following conditions: Postherpetic Neuralgia.
What interventions are being tested in trial NCT02365636?
The interventions under investigation include: Placebo (DRUG), TV-45070 (DRUG).
Who is sponsoring clinical trial NCT02365636?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02365636 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postherpetic Neuralgia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.